Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1985 1
1986 1
1990 3
1991 3
1992 2
1993 4
1994 1
1995 4
1996 6
1997 10
1998 4
1999 9
2000 14
2001 24
2002 15
2003 27
2004 18
2005 31
2006 26
2007 32
2008 30
2009 42
2010 41
2011 38
2012 50
2013 63
2014 72
2015 78
2016 80
2017 77
2018 63
2019 78
2020 77
2021 78
2022 84
2023 87
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,125 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: HSFGFR3EX
Page 1
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A, Scagliarini S, Crocetto F, Bianco R, Formisano L. Ascione CM, et al. Cancer Treat Rev. 2023 Apr;115:102530. doi: 10.1016/j.ctrv.2023.102530. Epub 2023 Feb 28. Cancer Treat Rev. 2023. PMID: 36898352 Free article. Review.
FGFR3 gene rearrangements are typical alterations in bladder cancer (Nelson et al., 2016; Parker et al., 2014). In this review, we summarize the most relevant evidence on the role of FGFR3 and the state-of-art of anti-FGFR3 treatment in bladder cancer. …
FGFR3 gene rearrangements are typical alterations in bladder cancer (Nelson et al., 2016; Parker et al., 2014). In this review …
FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ. Costa R, et al. Oncotarget. 2016 Aug 23;7(34):55924-55938. doi: 10.18632/oncotarget.10482. Oncotarget. 2016. PMID: 27409839 Free PMC article. Review.
Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR targeted therapies. FGFR gene aberrations and FGFR gene rearrangements are relatively rare in solid malignancies. The recently d …
Indeed, results from early phase clinical trials already indicate that a subset of patients with advanced tumors derive benefit from FGFR ta …
FGF receptors: cancer biology and therapeutics.
Katoh M, Nakagama H. Katoh M, et al. Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma. FGFR1 and FGFR3 genes are fused to neighboring TACC1 and TACC3 genes, res …
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in mul …
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. Helsten T, et al. Clin Cancer Res. 2016 Jan 1;22(1):259-67. doi: 10.1158/1078-0432.CCR-14-3212. Epub 2015 Sep 15. Clin Cancer Res. 2016. PMID: 26373574
EXPERIMENTAL DESIGN: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clinical Laboratory Improvement Amendments (CLIA) laboratory (Foundation Medicine) using next-generation sequencing (182 or 236 genes), and a …
EXPERIMENTAL DESIGN: We analyzed frequencies of FGFR aberrations in 4,853 solid tumors that were, on physician request, tested in a Clinical …
A molecular taxonomy for urothelial carcinoma.
Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M. Sjödahl G, et al. Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2. Clin Cancer Res. 2012. PMID: 22553347 Free article.
Tumor subtypes were validated in three independent publically available data sets. The expression of 11 key genes was validated at the protein level by immunohistochemistry. RESULTS: The subtypes show distinct clinical outcomes and differ with respect to expression of cell …
Tumor subtypes were validated in three independent publically available data sets. The expression of 11 key genes was validated at th …
Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Hiltbrunner S, et al. Br J Cancer. 2022 Nov;127(11):1997-2005. doi: 10.1038/s41416-022-01979-0. Epub 2022 Sep 22. Br J Cancer. 2022. PMID: 36138075 Free PMC article.
All tumours were sequenced with the FoundationOne or FoundationOneCDx assay for detection of substitutions, insertion-deletions, copy-number alterations and selected rearrangements in at least 324 cancer genes. RESULTS: This analysis revealed alterations in 19 genes …
All tumours were sequenced with the FoundationOne or FoundationOneCDx assay for detection of substitutions, insertion-deletions, copy-number …
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Walker BA, et al. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Blood. 2018. PMID: 29884741 Free PMC article.
Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary transloc …
Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. …
Bladder cancer genomics.
Siracusano S, Rizzetto R, Porcaro AB. Siracusano S, et al. Urologia. 2020 May;87(2):49-56. doi: 10.1177/0391560319899011. Epub 2020 Jan 16. Urologia. 2020. PMID: 31942831 Review.
By this way, bladder cancers can be classified as papillary or non-papillary based on genetic alterations with activation or mutations in FGFR3 papillary tumors and with inactivation or mutations involving TP53 and RB1 in non-papillary tumors. Recently, the patterns of …
By this way, bladder cancers can be classified as papillary or non-papillary based on genetic alterations with activation or mutations in …
FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH, Chen S, Wang Y, Jin S, Wang J, Ye D, Zhu X, Shen Y. Xu PH, et al. Comput Biol Med. 2023 Aug;162:106976. doi: 10.1016/j.compbiomed.2023.106976. Epub 2023 Apr 29. Comput Biol Med. 2023. PMID: 37301098
Further, the mFGFR3 status and mRNA expression profiles were analyzed to identify immune-related genes that were differentially expressed between patients with BLCA with wild-type FGFR3 or mFGFR3 in the TCGA training cohort. An FGFR3-related immune prognostic …
Further, the mFGFR3 status and mRNA expression profiles were analyzed to identify immune-related genes that were differentially expre …
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY. Rose TL, et al. Br J Cancer. 2021 Oct;125(9):1251-1260. doi: 10.1038/s41416-021-01488-6. Epub 2021 Jul 22. Br J Cancer. 2021. PMID: 34294892 Free PMC article.
Objective response rate to ICB, progression-free survival, and overall survival was compared between patients with FGFR3-alterations and those without. RNA expression, including molecular subtyping and T cell receptor clonality, was also compared between FGFR3-alter …
Objective response rate to ICB, progression-free survival, and overall survival was compared between patients with FGFR3-alterations …
1,125 results